Skip to content
Review Open access

Early diagnosis of pancreatic cancer: current diagnostic methods and the role of primary care physicians in improving outcomes - a narrative review

Sep 2026 · Journal of Education, Health and Sport · 0 citations · 35 references

TL;DR

A multimodal approach combining imaging, biomarkers, and emerging technologies is needed to improve outcomes, and greater awareness among primary care physicians and continued development of liquid biopsy and AI tools may improve outcomes.

Abstract

Pancreatic cancer is one of the most aggressive malignancies and a leading cause of cancer-related mortality worldwide. Prognosis remains poor due to late diagnosis, as early-stage disease is usually asymptomatic or presents with non-specific symptoms, and the lack of effective screening results in most patients being diagnosed at an advanced stage. This review evaluates challenges in pancreatic cancer diagnosis, summarizes available diagnostic methods, and highlights the role of primary care physicians in early detection. Evidence published between 2015 and 2026 was analyzed. A structured literature search was conducted using PubMed and Google Scholar. Search terms included "pancreatic cancer", "early diagnosis", "screening", "biomarkers", "imaging", "liquid biopsy", "circulating tumor DNA", and "artificial intelligence". Original studies, reviews, and clinical guidelines were included. CT remains the primary imaging modality, though sensitivity decreases for small lesions. Endoscopic ultrasound improves detection and enables tissue sampling. CA 19-9 has limited early diagnostic value. Liquid biopsy methods show promise but remain under validation. Radiomics and AI may enhance detection of subtle imaging features. Primary care physicians are essential for recognizing suspicious symptoms and ensuring timely referral. Early diagnosis remains challenging due to non-specific symptoms, limited screening, and diagnostic shortcomings. A multimodal approach combining imaging, biomarkers, and emerging technologies is needed. Greater awareness among primary care physicians and continued development of liquid biopsy and AI tools may improve outcomes.

Read PDF

Similar papers

Review Open access Oct 2026

Pancreatic Cancer Screening and Early Detection: Where Are We Now?

Pancreatic cancer remains one of the most lethal malignancies, with an overall 5-year survival rate of approximately 13%. The poor prognosis is primarily due to late-stage diagnosis, as early-stage disease is often asymptomatic. Screening for pancreatic cancer in high-risk individuals offers the potential for early det...

Shravya Srinivas Rao, Soumyadeep Ghosh, A. Goenka et al. · 2 citations
Review Open access Aug 2026

Role of liquid biopsy in the multimodal assessment and treatment of esophageal cancer: a surgical perspective.

Esophageal cancer (EC) remains a highly lethal malignancy, characterized by late diagnosis, early systemic dissemination, and high recurrence rates. Conventional diagnostic and surveillance strategies have limited sensitivity for early disease detection and minimal residual disease. Liquid biopsy technologies have emer...

A. Aiolfi, D. Bona, E. Rausa et al. · 0 citations
Review Open access Sep 2026

Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology

Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide, representing a major public health challenge. Although low-dose computed tomography is currently the standard screening method for high-risk individuals to reduce mortality, its clinical performance is limited by false-positive findings a...

Hicham Mansour, Omayma Mazouji, Ayman El Hammouti et al. · 0 citations
Review Open access Aug 2026

Liquid Biopsy for Molecular Residual Disease Detection and Postoperative Surveillance in Gastric Cancer: Current Evidence and Future Directions

The biological basis of molecular residual disease, liquid biopsy technologies, ctDNA data, the concept of molecular recurrence, and the future prospects of multi-analytic and artificial intelligence (AI)-assisted surveillance models in gastric cancer are summarized.

L. Lazaridou, Kalliopi Vakalou, A. Dimaki et al. · 0 citations
Review Open access Sep 2026

Precision Diagnostics in Prostate Cancer: Integrating Biomarkers, Imaging, Genomics, and Artificial Intelligence in Contemporary United States Practice

This review critically examines contemporary prostate cancer diagnostics within United States clinical practice, distinguishing established guideline-supported approaches from selectively used adjuncts and emerging technologies.

M. Kardjadj · 0 citations
Sep 2026

Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?

It is emphasized that the future effectiveness of PDAC prevention lies in refined risk stratification through universal germline testing, the integration of polygenic and environmental data, and the provision of comprehensive psychosocial support to manage the emotional impact of surveillance.

D. Campa, C. Rizzato, A. Kataki et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.